Brought to you by 
BioChem & SmithKline Beecham to develop influenza vaccines
13 Jul 1999
Executive Summary
BioChem Pharma and SmithKline Beecham Biologicals will jointly develop nasally administered influenza vaccines using BioChem's Phase II/III cell-derived vaccine technology.
Deal Industry
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
- Nasal
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioChem & SmithKline Beecham to develop influenza vaccines
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice